Gain Therapeutics Announces Proposed Public Offering
21 11월 2023 - 6:03AM
Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq:
GANX) today announced that it is proposing to offer and sell,
subject to market conditions, shares of its common stock and
warrants to purchase common stock in an underwritten public
offering. Gain expects to grant the underwriters a 30-day option to
purchase up to an additional 15% of the shares of common
stock and/or the warrants offered in the offering. All of the
shares of common stock and warrants are being offered by the
Company.
Gain intends to use the net proceeds from the
offering to continue clinical and nonclinical development of its
lead product candidate GT-02287 for the treatment of
neurodegenerative diseases including GBA1 Parkinson’s disease and
for general corporate purposes. The final terms of the offering
will depend on market and other conditions at the time of pricing,
and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the
offering.
Newbridge Securities Corporation is acting as
the sole book-running manager for the proposed offering.
The securities described above will be offered
pursuant to a shelf registration statement on Form S-3 (File No.
333-265061), which was previously filed with the Securities
and Exchange Commission (“SEC”) and became effective
on June 1, 2022. A preliminary prospectus supplement and
accompanying base prospectus relating to and describing the terms
of the offering and the concurrent private placement will be filed
with the SEC and will be available on the SEC’s website
located at www.sec.gov, copies of which may be obtained, when
available, for free by contacting Newbridge Securities
Corporation, Attn: Equity Syndicate Department, 1200 North Federal
Highway, Suite 400, Boca Raton, FL 33432, by email at
syndicate@newbridgesecurities.com or by telephone at (877)
447-9625.
The offering will be made only by means of a
prospectus. This press release does not constitute an offer to sell
or the solicitation of an offer to buy any of the securities
described herein, nor shall there be any sale of these securities
in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.
About Gain Therapeutics,
Inc.
Gain Therapeutics, Inc. is a clinical-stage
biotechnology company leading the discovery and development of next
generation allosteric therapies. Gain’s lead drug candidate
GT-02287, in development for the treatment of GBA1 Parkinson’s
disease, is currently being evaluated in a Phase 1 clinical
trial.
Leveraging AI-supported structural biology,
proprietary algorithms and supercomputer-powered physics-based
models, the company’s SEE-Tx® discovery platform can identify novel
allosteric binding sites on disease-implicated proteins,
pinpointing pockets that cannot be found or drugged with current
technologies. Gain’s unique approach enables the discovery of
novel, allosteric small molecule modulators that can restore or
disrupt protein function. Deploying its highly advanced platform,
Gain is accelerating drug discovery and unlocking novel
disease-modifying treatments for untreatable or difficult-to-treat
disorders including neurodegenerative diseases, rare genetic
disorders and oncology.
Forward Looking Statement
This release contains “forward-looking
statements” made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements
are typically preceded by words such as “believes,” “expects,”
“anticipates,” “intends,” “will,” “may,” “should,” or similar
expressions. These forward-looking statements reflect management’s
current knowledge, assumptions, judgment and expectations regarding
future performance or events. Although management believes that the
expectations reflected in such statements are reasonable, they give
no assurance that such expectations will prove to be correct or
that those goals will be achieved, and you should be aware that
actual results could differ materially from those contained in the
forward-looking statements. Forward-looking statements are subject
to a number of risks and uncertainties, including, but not limited
to, risks associated with market conditions and the satisfaction of
customary closing conditions related to the offering and
uncertainties related to the Company’s expectations regarding the
completion, timing and size of the proposed offering. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to the Company’s business in
general, please refer to the Company’s prospectus supplement to be
filed with the SEC, and the documents incorporated by reference
therein, including the Company’s Form 10-K for the year ended
December 31, 2022 and Forms 10-Q for the quarters ended March 31,
2023, June 30, 2023 and September 30, 2023.
All forward-looking statements are expressly
qualified in their entirety by this cautionary notice. You are
cautioned not to place undue reliance on any forward-looking
statements, which speak only as of the date of this release. We
have no obligation, and expressly disclaim any obligation, to
update, revise or correct any of the forward-looking statements,
whether as a result of new information, future events or
otherwise.
Investor & Media
Contact:
Susan SharpeLinnden Communications(919)
602-2330susan@linndencom.com
Gain Therapeutics (NASDAQ:GANX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Gain Therapeutics (NASDAQ:GANX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024